-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 30, Huluwa announced that it had recently received the "Drug Registration Certificate" for lansoprazole for injection approved and issued by the State Food and Drug Administration
.
The listing application was accepted by the Hainan Provincial Drug Administration in 2015
.
Up to now, Huluwa has invested a total of RMB 4,999,300 in research and development expenses for this product (unaudited)
Lansoprazole for injection was developed by TAP, a joint venture between Takeda and Abbott, and was approved by the US FDA on May 27, 2004.
In October 2006, Japan Takeda Pharmaceutical Co.
, Ltd.
was approved for listing in Japan.
The specifications are: 30mg, the original research has not been imported
.
According to data inquiries on the website of the State Food and Drug Administration, as of the announcement date, in addition to the gourd baby, 32 domestic companies including Shandong Luoxin Pharmaceutical Group Co.
